Compare Smith & Nephew plc (SNN) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Upstart Holdings Inc — how do they compare? Smith & Nephew plc trades at $30.14 (market cap $12.38B), while Upstart Holdings Inc trades at $30.9 (market cap $2.83B). The key difference: Smith & Nephew plc is far larger — about 4.4× Upstart Holdings Inc's market cap, and Smith & Nephew plc pays a 2.66% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| SNN | UPST | |
|---|---|---|
Market Cap | $12.38B | $2.83B |
Sector | Health | Financials |
52-Week High | $38.70 | $73.76 |
52-Week Low | $28.73 | $24.22 |
Enterprise Value | $15.41B | — |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.11, up 0.33% today, with a bearish technical signal but improving fundamentals. Recent earnings show mixed results, beating in Q4 2025 and Q2 2026 but missing earlier quarters. Revenue growth has accelerated from $5.2B in 2022 to $6.16B in 2025, with net income margin expanding to 10.08%. The company maintains a dividend, with the next payment scheduled for November 2026. News highlights include product launches in robotics and wound care, though Q2 2026 revenue growth fell short of expectations.
Outlook is cautiously optimistic due to solid profitability and innovation, but risks include U.S. market softness and competitive pressures. Analysts largely recommend Hold, reflecting balanced growth potential against execution challenges. The stock's valuation at a P/E of 20.3 appears reasonable if earnings momentum continues, but investors should monitor operational execution closely.
Upstart (UPST) trades at $30.97, up 3.61% today, but remains bearish technically with recent earnings misses. The company reported a return to GAAP profitability in 2025 with $1.02B revenue and $53.60M net income, yet cash flow from operations was negative. Analyst consensus is mixed with a $47.20 price target, reflecting cautious optimism amid high valuation multiples.
The outlook hinges on execution of AI-driven loan underwriting growth and margin improvement, but risks include volatile cash flows, rising debt, and sensitivity to interest rates. Investors face a balance between growth potential and financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
